Abbott Pays $400 Million Upfront For Reata’s Preclinical AIM Programs
This article was originally published in The Pink Sheet Daily
Executive Summary
Adding on to the two companies’ collaboration around chronic kidney disease candidate bardoxolone, Abbott will pay a record upfront for preclinical assets to co-develop and co-commercialize Reata’s antioxidant inflammation modulators in a variety of disease areas.
You may also be interested in...
Abbott Adds To Renal Pipeline In Deal With Action Pharma
For a single $110 million payment, the soon-to-be-split Abbott gets global rights to AP214, a Phase IIb compound designed to prevent acute kidney damage caused by hypoxia during cardiac surgery.
Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug
As its pharma division separates from its diversified medical products unit, Abbott obtains another drug that could succeed Humira in rheumatoid arthritis and related indications.
Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug
As its pharma division separates from its diversified medical products unit, Abbott obtains another drug that could succeed Humira in rheumatoid arthritis and related indications.